In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
Similar to results among people who smoked traditional cigarettes, e-cigarette smoking negatively effects heart disease risk factors, namely, cholesterol, triglycerides and glucose levels, and decreases blood flow in the heart.
This study assessed improvement in pulmonary vascular resistance and cardiac index in patients with pulmonary arterial hypertension who rapidly inhale iloprost 2.5 ug via the Breelib™ nebulizer.
Researchers evaluated whether cardiopulmonary exercise testing could improve the performance of the DETECT screening approach in systemic sclerosis-related pulmonary arterial hypertension.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
Clinical experts in pulmonary arterial hypertension (PAH) identified certain hemodynamic variables as predictive of patient survival that were different from variables found in major clinical trials.
Investigators used quantitative echocardiographic methods to examine symptoms, mortality risk, and cardiac remodeling sequalae related to pulmonary hypertension in an effort to improve understanding of pulmonary hypertension.
The FDA has approved the supplemental NDA for Orenitram extended-release tablets for the treatment of PAH to delay disease progression, in addition to improving exercise capacity.
Twice-daily selexipag was associated with improvements in 6-minute walk distance and potential maintenance or improvement in World Health Organization functional class in patients with pulmonary arterial hypertension.
Current guidelines recommend 5 weeks of postoperative prophylactic anticoagulation, but a new study suggests the duration of this treatment ought to be extended.
